Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $201.62, giving the company a market capitalization of 485.91B. It carries a P/E multiple of 19.49 and pays a dividend yield of 2.5%.
On 2025-12-09, Johnson & Johnson(JNJ) stock moved within a range of $200.99 to $203.26. With shares now at $201.62, the stock is trading +0.3% above its intraday low and -0.8% below the session's peak.
Trading volume for Johnson & Johnson(JNJ) stock has reached 7.78M, versus its average volume of 8.73M.
The stock's 52-week range extends from a low of $140.68 to a high of $207.81.
The stock's 52-week range extends from a low of $140.68 to a high of $207.81.
JNJ News
Johnson & Johnson (JNJ) keeps grinding higher, and with the stock up roughly 14% over the past 3 months and nearly 40% year to date, investors are asking what i...
Why 2026 Could Be the Breakout Year for Dividend Growth Investors Quick Read Procter & Gamble (PG) has raised dividends for 69 consecutive years with a current...
Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader m...
Analyst ratings
59%
of 27 ratingsMore JNJ News
Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ) have secured spots on China’s drug catalog, with a total of 19 medicines making the list, Amber Tong...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment wi...
(RTTNews) - Johnson & Johnson (JNJ) announced updated results from the Phase 3 CARTITUDE-4 study, reinforcing the potential of CARVYKTI (ciltacabtagene autoleuc...
Insiders have been trading these 5 stocks: ((NVDA)), ((MSFT)), ((SMCI)), ((JNJ)) and ((MCD)). Here is a breakdown of their recent trades and their value. TipRan...
Johnson & Johnson announced that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system...
Wondering if Johnson & Johnson is still attractively priced at today’s level, or if the big gains are already behind it? Let’s unpack what the numbers are reall...